Spectrum Pharmaceuticals buy (Brean Murray, Carret & Co., LLC) 10.10.2007 | Analyse

DAX	6.693	-1,4%	Dow	12.801	-0,7%	Euro	1,3200	-0,7%
ESt50	2.481	-1,7%	Nas	2.904	-0,8%	Öl	117,6	-0,9%
TDax	769,9	-0,4%	Nikkei	8.947	-0,6%	Gold	1.721	-0,5%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze		Kursziele		Insidertrades	Knock-outs	myfinanzen
Orderbuch	Realtime Stuttgart	RSS Feed		im Forum	Fonds	Senden/Drucken
Historisch	Realtime Push			IR-Daten	Anleihen	handeln

Zusammenfassung: Spectrum Pharmaceuticals buy
Unternehmen: Spectrum Pharmaceuticals IncShs	Analyst: Brean Murray, Carret & Co., LLC	Kursziel: -
Rating jetzt: buy	Kurs*: 4,61 USD	Abst. Kursziel*: -
Rating vorher: hold	Kurs aktuell: 14,09 USD	Abst. Kursziel aktuell: -
Analyst Name: -	KGV*: -	Ø Kursziel: -

Relevant
Alle
vom Unternehmen

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

02.12.11	Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments (EN, Forbes)
22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
23.09.11	Does Spectrum Pharmaceuticals Have a Bright Future? (EN, Benzinga earnings)
30.06.11	Hearing Chatter that Globes Believes Spectrum Pharmaceuticals Could be Takeover Target (EN, Benzinga rumors)
16.06.11	Which Path Will Spectrum Pharmaceuticals Take? (EN, MotleyFool)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

02.12.11	Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments (EN, Forbes)
23.09.11	Does Spectrum Pharmaceuticals Have a Bright Future? (EN, Benzinga earnings)
30.06.11	Hearing Chatter that Globes Believes Spectrum Pharmaceuticals Could be Takeover Target (EN, Benzinga rumors)
16.06.11	Which Path Will Spectrum Pharmaceuticals Take? (EN, MotleyFool)

22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

25.03.11	Spectrum Pharmaceuticals outperform	RBC Capital Markets
14.10.09	Spectrum Pharmaceuticals market outperform	Rodman & Renshaw, LLC
20.08.08	Spectrum Pharmaceuticals chancenreich	Der Aktionär
24.04.08	Spectrum Pharmaceuticals Downgrade	Oppenheimer & Co. Inc.
19.03.08	Spectrum Pharmaceuticals Downgrade	Brean Murray, Carret & Co., LLC

25.03.11	Spectrum Pharmaceuticals outperform	RBC Capital Markets
14.10.09	Spectrum Pharmaceuticals market outperform	Rodman & Renshaw, LLC
20.08.08	Spectrum Pharmaceuticals chancenreich	Der Aktionär
14.11.07	Spectrum Pharmaceuticals Position aufbauen	Biotech-Report
10.10.07	Spectrum Pharmaceuticals buy	Brean Murray, Carret & Co., LLC

24.04.08	Spectrum Pharmaceuticals Downgrade	Oppenheimer & Co. Inc.
19.03.08	Spectrum Pharmaceuticals Downgrade	Brean Murray, Carret & Co., LLC
26.07.07	Spectrum Pharmaceuticals Downgrade	Friedman, Billings Ramsey & Co

10.02.12	Daimler buy
10.02.12	Infineon Technologies buy
10.02.12	Allianz buy
10.02.12	AIXTRON SE buy
10.02.12	K+S outperform
10.02.12	Software neutral
10.02.12	Daimler outperform
10.02.12	Q-Cells sell
10.02.12	United Internet hold
10.02.12	Singulus Technologies buy
10.02.12	SAP underperform
10.02.12	Merck verkaufen
10.02.12	freenet buy
10.02.12	adidas halten
10.02.12	Daimler equal-weight
10.02.12	HeidelbergCement hold
10.02.12	Daimler hold
10.02.12	ThyssenKrupp halten
10.02.12	Daimler buy
10.02.12	Deutsche Lufthansa buy
10.02.12	HeidelbergCement buy
10.02.12	RWE buy
10.02.12	Infineon Technologies hold
10.02.12	Infineon Technologies hold
10.02.12	Deutsche Post overweight
10.02.12	centrotherm photovoltaics buy
10.02.12	Daimler hold
10.02.12	Daimler buy
10.02.12	BMW overweight
10.02.12	AIXTRON SE hold
10.02.12	Deutsche Lufthansa kaufen
10.02.12	HeidelbergCement kaufen
10.02.12	Deutsche Telekom outperform
09.02.12	Daimler outperform
09.02.12	Daimler halten
09.02.12	Daimler verkaufen
09.02.12	Allianz neutral
09.02.12	BMW neutral
09.02.12	HeidelbergCement add
09.02.12	Singulus Technologies kaufen

Wie investieren Sie Ihr Geld?
	Ich kaufe überwiegend selbständig Aktien.
	Ich investiere mein Geld hauptsächlich in Fonds.
	Ich handle meistens mit Hilfe von Zertifikaten oder anderen komplexen Derivaten.
	Ich interessiere mich zwar für die Börse, lasse mein Geld aber lieber auf einem Festgeld- oder Tagesgeldkonto.
	Ich investiere mein Geld in Bausparverträge und Lebensversicherungen. Der Rest kommt auf ein Sparbuch.
Direkt zu den Ergebnissen Abstimmen

Finanzen.net

Spectrum Pharmaceuticals Aktie [WKN: 164623 / ISIN: US84763A1088]

10.10.2007 08:16

Spectrum Pharmaceuticals buy

Kommentare zu diesem Artikel

Analysen zu Spectrum Pharmaceuticals IncShs

Nachrichten zu Spectrum Pharmaceuticals IncShs

Analysensuche

AKTIEN IN DIESEM ARTIKEL

ANZEIGE

Aktuelle Analysen

TOP-RANKINGS

Umfrage